Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity
ACS Applied Bio Materials · 2024
DOI: 10.1021/acsabm.4c00719 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2024. Verfasst von Roopjyoti Misra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India. Hauptthemen laut MEDLINE: Prodrugs, Aldehyde Reductase, Antineoplastic Agents, Rhodanine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Indian Institute of Technology Guwahati, Science and Engineering Research Board.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India.
ORCID-Profile: Krishna P Bhabak
Förderung
- Council of Scientific and Industrial Research, India
- Indian Institute of Technology Guwahati
- Science and Engineering Research Board
Zitieren
APA
Misra, R., Barman, P., & Bhabak, K. P. (2024). Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.4c00719
Vancouver
Misra R, Barman P, Bhabak KP. Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity. ACS Applied Bio Materials. 2024. doi:10.1021/acsabm.4c00719
BibTeX
@article{Misra2024,
author = {Misra, Roopjyoti and Barman, Pallavi and Bhabak, Krishna P},
title = {Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity},
journal = {ACS Applied Bio Materials},
year = {2024},
doi = {10.1021/acsabm.4c00719}
}
EUVIMED